Bayer And Kythera Strike Licensing Deal in Aesthetic Dermatology
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer's Intendis skin care unit bets on a niche drug that is likely to depend on out-of-pocket payments.
You may also be interested in...
Botox Reimbursement Training Is Driving Factor In Allergan Settlement With DOJ
Allergen will pay $600 million for promoting the drug for headache and spasticity; government says company taught physicians how to bill for off-label uses.
Medical Dermatology Gets Under VCs' Skin
In the pharmaceutical industry, dermatology is the new ophthalmology. Like ophtho, dermatology has long been viewed as a pharmaceutical backwater dogged by a diverse set of problems, including a fragmented market, drug delivery challenges, and less than effective therapies. Today's market forces, however, are driving Big Pharma into a more specialized direction, and in the past three years, many - if not all - Big Pharmas have reoriented their pipelines, refocusing on areas of high unmet medical need in the hopes of identifying novel drugs that have a greater chance of passing muster with regulators and succeeding in the marketplace. Freed from the need to pursue blockbuster products, dermatology assets are suddenly more attractive.
Intendis: Mid-Sized Specialist Spawns Small Specialist
In dermatology offshoot Intendis, Schering AG has created the ideal European crossbreed: a group with the management experience associated with spin-outs, and a revenue-generating side more typical of specialty pharma. The snag: Schering's retaining full ownership--for now.